4th AOPMC Scientific Program

Please note that the times, titles and topics are subject to change.

Download version here. (Get Acrobat Reader™ here.)

Friday, November 28

12:45-13:45 - Opening Symposium: Balancing efficacy and adverse events of dopamine agonist in PD management (Sponsored by Boehringer-Ingelheim) - Tim Anderson (New Zealand) and Yoshikuni Mizuno (Japan)

14:00-15:00 - Opening Symposium: Complementing clinical examinations in targeting muscles for botulinum toxin injection: Methods of localization by using cervical dystonia as a model (Sponsored by Allergan) - Priya Jagota (Thailand) and Erle Lim (Singapore)

15:30-16:30 - Opening Symposium: Practical tips for managing complications in advanced Parkinson's disease (Sponsored by Novartis) - Werner Poewe (Austria) and Nobutaka Hattori (Japan)

16:45-17:45 - Opening Symposium: A holistic view of Parkinson's disease (Sponsored by Abbott-UCB) - K. Ray Chaudhuri (United Kingdom) and Thomas Kimber (Australia)

18:00 - 19:00 - Opening Ceremony

19:00 - 19:30 - Welcome Reception

19:30-20:30 - Dinner Symposium: Optimizing Parkinson's disease pharmacotherapy (Sponsored by Lundbeck) - Heinz Reichmann (Germany)

Saturday, November 29

08:00-09:30 - Plenary Session I: Perspectives on Parkinson's disease: Past accomplishments and future
8:00 - Evolving clinicopathological concepts of Parkinson's disease: Moving beyond the "Decade of the Brain" - Werner Poewe (Austria)
8:30 - Indications for using biomarkers for the diagnosis of Parkinson's disease: Options for various scenarios - Anthony Lang (Canada)
9:00 - Insights into the natural history of Parkinson's disease: What is the appropriate therapy for patients in different stages? - Victor Fung (Australia)

10:00-11:30 - Plenary Session II: Therapeutics in Parkinson's disease: The Asian-Oceanian viewpoint - Shen-Yang Lim (Malaysia)
10:00 - Pharmacological, surgical, and infusional therapies in Parkinson's disease: A closer look at the Asian-Oceanian data - Shen-Yang Lim (Malaysia)
10:30 - Asian complementary practices in the management of Parkinson's disease: Applications and evidence - Beom Jeon (Korea)
11:00 - The use of neurorestorative technologies in Parkinson's disease: Asian-Oceanian experiences - Ryosuke Takahashi (Japan)

11:30-12:30 - Poster Session A

13:00-14:00 - Lunch Symposium: Partnerships beyond the technology (Sponsored by Medtronic) - Chong Sik Lee (Korea) and Peter Silburn (United Kingdom)

14:30-16:00 - Parallel Sessions

Parallel Session 1211: Effective management of PD symptoms (motor and nonmotor) fluctuations in clinical practice (Supported by Roche)
14:30 - Clinicopathologic correlations of symptom (motor and non motor) fluctuations in Parkinson’s disease - Francisco Cardoso (Brazil)
15:00 - Symptom fluctuations in PD: Boundaries beyond recognition - Ruey-Meei Wu (Taipei)
15:30 - How can medications be adjusted to minimize symptom fluctuations? Basic principles - Shengdi Chen (China)

Parallel Session 1212: Physiological studies in movement disorders: When do clinicians need them and practical interpretation?
14:30 - Electrophysiological studies on tremor, myoclonus and dystonia - Ryuji Kaji (Japan)
15:00 - Diagnostic and therapeutic roles of rTMS in movement disorders - Yoshikazu Ugawa (Japan)
15:30 - Electrophysiological studies in peripheral movement disorders - Jou-Hsien Chen (Taipei)

Parallel Session 1213: Diagnostic clues from neuroimaging: Practical tips for clinicians
14:30 - Parkinsonism - Chong-Sik Lee (South Korea)
15:00 - Non-parkinsonian disorders - Mohit Bhatt (India)
15:30 - Interactive session: Radiological diagnosis - Oraporn Sitburana (Thailand)

16:30-18:00 - Parallel Sessions

Parallel Session 1224: Defrosting PD and understanding "freezing of gait" (FOG) and falls
16:30 - Subclinical gait and postural dysfunction in early PD: Time for intervention? - Simon Lewis (Australia)
17:00 - The physiological and clinical dynamics of FOG and falls - Yasuyuki Okuma (Japan)
17:30 - Implementing effective strategies to reduce FOG and falls in PD patients--medications, training, devices and home modifications - Meg Morris (Australia)

Parallel Session 1225: Recognition and management of movement disorders conditions in general medical practice
16:30 - Movement disorders in intensive care units: Differentiation from mimics and therapeutic priorities - Chusak Limotai (Thailand)
17:00 - Movement disorders in autoimmune and neoplastic disorders - Eng-King Tan (Singapore)
17:30 - Movement disorders in metabolic disorders - Norlinah Ibrahim (Malaysia)

Parallel Session 1226: Chorea in clinical practice
16:30 - Clinical Clues to look for that help define your differential diagnosis - Philip Thompson (Australia)
17:00 - Diagnostic work-up in chorea: Practical considerations - HuiFang Shang (China)
17:30 - Spectrum and management of drug-induced movement disorders - Sith Sathornsumetee (Thailand)

18:30-19:30 - Dinner Symposium: Optimizing the role of botulinum toxin in the management of hemifacial spasm and blepharospasm (sponsored by Ipsen) - Raymond Rosales (Philippines) and Shen-Yang Lim (Malaysia)

20:00 - 22:00 - Video Tournament

Sunday, November 30

08:30 - 10:00 - MDS Lectureship Awards: Yoshikuni Mizuno Award Lecture and Philip Thompson
Award Lecture

10:30-12:00 - Plenary Session III: Specific movement disorders in the Asian-Oceanian region: Historical
and recent developments

10:30 - Sex-linked recessive dystonia parkinsonism of Panay - Lilian Lee (Philippines)
11:00 - Segawa's disease and Parkinsonisms, ALS, Dementia complex of Kii Peninsula - Shigeki Kuzuhara (Japan)
11:30 - Common movement disorders in the Asian-Oceanian region - Roongroj Bhidayasiri (Thailand)

12:00-13:00 - Poster Session B

13:30-14:30 - Lunch Symposium: Apomorphine in Parkinson's disease: Clinical evidence and best practice (Sponsored by Britannia) - Teus van Laar (Netherlands) and Roongroj Bhidayasiri (Thailand)


15:00-16:30 - Parallel Sessions

Parallel Session 2217: Clinical signs that assist clinicians in making a diagnosis of a movement disorder condition
15:00 - Parkinsonian disorders - Oscar Gershanik (Argentina)
15:30 - Hyperkinesias - Asha Kishore (India)
16:00 - Psychogenic movement disorders - Mark Hallett (USA)

Parallel Session 2218: Surgery of movement disorders
15:00 - Evolution of surgical therapy for PD and dystonia: Where are we now? - Sun Ha-Paek (Korea)
15:30 - Various targets of PD surgery: Practical considerations for clinicians - Jawad A. Bajwa (Saudi Arabia)
16:00 - Troubleshooting common surgical complications and DBS issues in PD and dystonia - Apichart Pisarnpong (Thailand)

Parallel Session 2219: Management strategies of difficult problems in movement disorders
15:00 - Management of autonomic dysfunction in parkinsonism - Miho Murata (Japan)
15:30 - Management of sleep problems in parkinsonism - Madhuri Behari (India)
16:00 - Management of heredodegenerative ataxias - Hidehiro Mizusawa (Japan)

17:00-18:30 - Parallel Sessions

Parallel Session 2310: Nutritional considerations and gastrointestinal dysfunction in PD: Practical Management
17:00 - Effective management of swallowing difficulty and dysphagia in PD - Sarah Ko (Singapore)
17:30 - The contributions of gastrointestinal dysfunction to weight loss in PD: What are the therapeutic options? - K. Ray Chaudhuri (United Kingdom)
18:00 - Nutritional tips for PD: Prevent weight loss, optimize absorption of levodopa and enhance musculoskeletal and cognitive fitness - Juei-Jueng Lin (Taipei)

Parallel Session 2311: Movement disorders in vascular diseases and hydrocephalus
17:00 - Poststroke movement disorders: Strategic locations, spectrum and management - Jonas Yeung (Hong Kong)
17:30 - From 'atherosclerotic' to 'vascular' parkinsonism: Evolving concept and therapeutic principles - Pramod Pal (India)
18:00 - Clinical complexity of hydrocephalus and parkinsonism: Optimal balance between medical and surgical management - Masakazu Miyajima (Japan)

Parallel Session 2312: Understanding neuropsychiatric manifestations in PD and atypical parkinsonisms
17:00 - Cognitive impairment and behavioural disorders - Hee Tae Kim (Korea)
17:30 - Multisensory hallucinations and delusions - Praween Lolekha (Thailand)
18:00 - Impulse control disorders/ Behavioral addictions - Thomas Kimber (Australia)

AOPMC Session Topics

Plenary Sessions
  • Perspectives on Parkinson's disease: Past accomplishments and future possibilities
  • Therapeutics in Parkinson's disease: The Asian-Oceanian viewpoint
  • Specific movement disorders in the Asian-Oceanian region: Historical and recent developments
     
Lectureship Awards
  • Yoshikuni Mizuno Lectureship Award Recipient Nobutaka Hattori:
    Pathogenesis of Parkinson's disease: Mechanistic insights from gene functions of monogenic forms of Parkinson's disease
     
  • Philip Thompson Lectureship Award Recipient Robert Iansek:
    Comprehensive care in Parkinson's disease: Are we ready yet?"
     
Parallel Sessions
  • Clinical signs that assist clinicians in making a diagnosis of a movement disorder condition
  • Defrosting PD and understanding "freezing of gait (FOG)" and falls
  • Nutritional considerations in PD management
  • Recognition and management of movement disorders conditions in general medical practice
  • Surgery of movement disorders
  • Effective management of PD symptom fluctuations (motor and non-motor) in clinical practice
  • Movement disorders in vascular diseases and hydrocephalus
  • Understanding neuropsychiatric manifestations in PD and atypical parkinsonisms
  • Physiological studies in movement disorders: When do clinicians need them and practical interpretation
  • Diagnostic clues from neuroimaging: Practical tips for clinicians
  • Chorea in clinical practice
  • Management strategies for difficult problems in movement disorders
     
Corporate Symposia
  • Balancing efficacy and adverse events of dopamine agonist in PD management – Supported by Boehringer-Ingelheim
  • Complementing clinical examinations in targeting muscles for botulinum toxin injection: Methods of localization by using cervical dystonia as a model – Supported by Allergan
  • Practical tips for managing complications in advanced Parkinson's disease – Supported by Novartis
  • A holistic view of Parkinson's disease – Supported by Abbott-UCB
  • Optimizing Parkinson's disease pharmacotherapy – Supported by Lundbeck
  • Partnerships beyond the technology – Supported by Medtronic
  • Optimizing the role of botulinum toxin in the management of hemifacial spasm and blepharospasm – Supported by Ipsen
  • Apomorphine in Parkinson's disease: Clinical evidence and best practice – Supported by Britannia
     
Top